118 related articles for article (PubMed ID: 23207289)
41. [Expression of P53, P63, and C-erbB-2 in endometrioid adenocarcinoma and their clinicopathological significance].
Hu WF; Liu MQ; Zhao Q
Ai Zheng; 2004 Sep; 23(9):1021-5. PubMed ID: 15363194
[TBL] [Abstract][Full Text] [Related]
42. CD44 variant 6 in endometrioid carcinoma of the uterus: its expression in the adenocarcinoma component is an independent prognostic marker.
Hoshimoto K; Yamauchi N; Takazawa Y; Onda T; Taketani Y; Fukayama M
Pathol Res Pract; 2003; 199(2):71-7. PubMed ID: 12747468
[TBL] [Abstract][Full Text] [Related]
43. p53 is correlated with low BMI negative progesterone receptor status and recurring disease in patients with endometrial cancer.
Seeger A; Kölbl H; Petry IB; Gebhard S; Battista MJ; Böhm D; Steiner E
Gynecol Oncol; 2012 Apr; 125(1):200-7. PubMed ID: 22210468
[TBL] [Abstract][Full Text] [Related]
44. Assessment of inhibin and p53 in granulosa cell tumors of the ovary.
Gebhart JB; Roche PC; Keeney GL; Lesnick TG; Podratz KC
Gynecol Oncol; 2000 May; 77(2):232-6. PubMed ID: 10785470
[TBL] [Abstract][Full Text] [Related]
45. Does the type of surgery for early-stage endometrial cancer affect the rate of reported lymphovascular space invasion in final pathology specimens?
Momeni M; Kolev V; Cardenas-Goicoechea J; Getrajdman J; Fishman D; Chuang L; Kalir T; Rahaman J; Zakashansky K
Am J Obstet Gynecol; 2013 Jan; 208(1):71.e1-6. PubMed ID: 23099190
[TBL] [Abstract][Full Text] [Related]
46. WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis.
Kumar-Singh S; Segers K; Rodeck U; Backhovens H; Bogers J; Weyler J; Van Broeckhoven C; Van Marck E
J Pathol; 1997 Jan; 181(1):67-74. PubMed ID: 9072005
[TBL] [Abstract][Full Text] [Related]
47. Allelic loss at TP53 is not related to p53 protein overexpression in primary human endometrial carcinomas.
Semczuk A; Marzec B; Skomra D; Roessner A; Cybulski M; Rechberger T; Schneider-Stock R
Oncology; 2005; 69(4):317-25. PubMed ID: 16293976
[TBL] [Abstract][Full Text] [Related]
48. Immunohistochemical and in situ hybridization analysis of p53 in human endometrial carcinoma of the uterus.
Jiko K; Sasano H; Ito K; Ozawa N; Sato S; Yajima A
Anticancer Res; 1993; 13(2):305-10. PubMed ID: 8517643
[TBL] [Abstract][Full Text] [Related]
49. Investigation of Insulin-Like Growth Factor-1 (IGF-1), P53, and Wilms' Tumor 1 (WT1) Expression Levels in the Colon Polyp Subtypes in Colon Cancer.
Aslan A; Erdem H; Celik MA; Sahin A; Cankaya S
Med Sci Monit; 2019 Jul; 25():5510-5517. PubMed ID: 31341157
[TBL] [Abstract][Full Text] [Related]
50. [Immunohistochemical study of PCNA, p53 gene product and c-erbB-2 gene product in endometrial carcinoma].
Miyazaki M
Nihon Sanka Fujinka Gakkai Zasshi; 1996 Apr; 48(4):269-76. PubMed ID: 8936111
[TBL] [Abstract][Full Text] [Related]
51. Accuracy of preoperative curettage in determining tumor type and grade in endometrial cancer.
Thanachaiviwat A; Thirapakawong C; Leelaphatanadit C; Chuangsuwanich T
J Med Assoc Thai; 2011 Jul; 94(7):766-71. PubMed ID: 21774280
[TBL] [Abstract][Full Text] [Related]
52. Expression level of Wilms tumor 1 (WT1) protein has limited prognostic value in epithelial ovarian cancer: from the Danish "MALOVA" ovarian cancer study.
Høgdall EV; Christensen L; Kjaer SK; Blaakaer J; Christensen IJ; Gayther S; Jacobs IJ; Høgdall CK
Gynecol Oncol; 2007 Aug; 106(2):318-24. PubMed ID: 17540436
[TBL] [Abstract][Full Text] [Related]
53. WT1 expression correlates with angiogenesis in endometrial cancer tissue.
Dohi S; Ohno S; Ohno Y; Kyo S; Soma G; Sugiyama H; Inoue M
Anticancer Res; 2010 Aug; 30(8):3187-92. PubMed ID: 20871039
[TBL] [Abstract][Full Text] [Related]
54. Simultaneous expression of the ras p21 and p53 proteins in human endometrial carcinomas.
Miturski R; Semczuk A; Jakowicki J
Acta Histochem; 1996 Nov; 98(4):411-8. PubMed ID: 8960305
[TBL] [Abstract][Full Text] [Related]
55. Immunohistochemical study of apoptosis-related Bcl-2 protein and its correlation with proliferation indices (Ki67, PCNA), tumor suppressor genes (p53, pRb), the oncogene c-erbB-2, sex steroid hormone receptors and other clinicopathological features, in normal, hyperplastic and neoplastic endometrium.
Mitselou A; Ioachim E; Kitsou E; Vougiouklakis T; Zagorianakou N; Makrydimas G; Stefanaki S; Agnantis NJ
In Vivo; 2003; 17(5):469-77. PubMed ID: 14598611
[TBL] [Abstract][Full Text] [Related]
56. High levels of Wilms' tumor 1 (WT1) expression were associated with aggressive clinical features in ovarian cancer.
Liu Z; Yamanouchi K; Ohtao T; Matsumura S; Seino M; Shridhar V; Takahashi T; Takahashi K; Kurachi H
Anticancer Res; 2014 May; 34(5):2331-40. PubMed ID: 24778040
[TBL] [Abstract][Full Text] [Related]
57. Immunoexpression of PAX 8 in endometrial cancer: relation to high-grade carcinoma and p53.
Brunner AH; Riss P; Heinze G; Meltzow E; Brustmann H
Int J Gynecol Pathol; 2011 Nov; 30(6):569-75. PubMed ID: 21979593
[TBL] [Abstract][Full Text] [Related]
58. Wilms' tumor 1 protein expression in endometrial adenocarcinoma and endometrial intra-epithelial neoplasia.
Atik Y; Cetinkaya Demir B; Ozan H; Baykara S; Usubutun A; Yılmaz Erturk F
J Obstet Gynaecol Res; 2016 Jul; 42(7):870-5. PubMed ID: 27062662
[TBL] [Abstract][Full Text] [Related]
59. A Proposed Kinetic Model for the Diagnostic and Prognostic Value of WT1 and p53 in Acute Myeloid Leukemia.
Bani-Ahmad MA; Al-Sweedan SA; Al-Asseiri MA; Alkhatib AJ
Clin Lab; 2018 Mar; 64(3):357-363. PubMed ID: 29739109
[TBL] [Abstract][Full Text] [Related]
60. Expression of γ-H2AX in endometrial carcinomas: an immunohistochemical study with p53.
Brunner AH; Hinterholzer S; Riss P; Heinze G; Weiss K; Brustmann H
Gynecol Oncol; 2011 Apr; 121(1):206-11. PubMed ID: 21185067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
